Ponatinib is available under the brand name “Iclusig”. It belongs to the drug class of Antineoplastic and Tyrosine Kinase Inhibitor”. It is indicated for the treatment of adults with chronic, accelerated, or blast-phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy, or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. This pharmaceutical medicine can be taken with or without a meal. In case of a missed dose, take the next scheduled dose the following day. Storing at a temperature of 20-25oC (68-77oF); excursions to 15-30oC are permitted. The most common non-hematologic adverse reactions related to this pharmaceutical medicine include hypertension, rash, abdominal pain, dry skin, constipation, arthralgia, and pyrexia. The hematologic adverse reactions include thrombocytopenia, anaemia, neutropenia, lymphopenia, and leukopenia. Your doctor or pharmacist should be informed of your medical history before you take this medicine, especially if you have: liver disease; heart problems (such as angina; high blood pressure); a previous stroke or mini-stroke (transient ischemic attack); diabetes; high cholesterol; and tobacco use. Verify the pregnancy status of females of reproductive potential before beginning the procedure. There is no information on the drug's presence in human milk, its effects on breastfed infants, or its effects on milk production. Women should not breastfeed during treatment and for 6 days after the last dose U.S. Food and Drug Administration has approved Ponatinib for adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Ponatinib is a kinase inhibitor with multiple targets. There is a constitutively active protein in CML known as Bcr-Abl. It inhibits Abl and T315I mutant kinase tyrosine kinase activity. Due to its ability to block the binding of Bcr-Abl inhibitors, the T315I mutation confers resistance in cells.

A 30-tablet supply of Ponatinib oral tablet 10 mg costs approximately $18,711, depending on the pharmacy you visit.

Pipelinepharma is a global online marketplace. It is structured to simplify pharmaceutical deals by providing its customers with an intuitive interface that is easy to engage with. The Ponatinib manufacturers and suppliers list can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. These advanced filters can also filter out the countries for this medicine’s manufacturers and suppliers. These also enable you to check the dossier status of this medicine, and the GMP approvals of the different variants of Ponatinib. Each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Ponatinib is manufactured in

Pipelinepharma is a legitimate online pharmaceutical marketplace, which provides a secure and safe B2B platform for drug dealers, wholesalers, and buyers. Sellers with a pharmaceutical license can register and can advertise as many drugs as they want. Moreover, the sellers can interact with the drug distributors and provide tertiary services directly to the buyers.

Pipelinepharma ensures that only validated manufacturers and wholesalers enter their advertising platform through their pre-auditing and quality control operations, providing a safe B2B pharmaceutical sales platform.